Physician profile
Thomas S Bailey
NPI 1598714818
$5,322.30
in general payments reported to CMS, 2019-2025
31 companies · $688 in 2025
The $688 reported for 2025 was more than what 86% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,803 · 2020: $360 · 2021: $735 · 2022: $903 · 2023: $462 · 2024: $371 · 2025: $688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,521.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,827.11 | 2019-2023 | Lo Loestrin Fe |
| Mayne Pharma Commercial LLC | $457.25 | 2022-2025 | |
| Hologic Sales and Service, LLC | $293.92 | 2019-2025 | Aptima |
| Pfizer INC. | $264.01 | 2020-2025 | |
| Siemens Medical Solutions USA, INC. | $214.48 | 2023-2025 | Embozene, Microthermx Microwave Ablation System, Oncozene |
| Daiichi Sankyo INC. | $209.37 | 2019-2022 | |
| Aspira Women'S Health INC | $208.50 | 2021-2024 | Ova1 |
| Biogen, INC. | $190.83 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $186.93 | 2019-2020 | |
| Astellas Pharma US INC | $159.29 | 2019-2025 | Veozah |
| Duchesnay USA Incorporated | $159.27 | 2019 | |
| Myovant Sciences INC. | $158.17 | 2021 | |
| Janssen Pharmaceuticals, INC | $143.75 | 2025 | Spravato |
| Lupin INC. | $129.75 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $129.39 | 2019-2025 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $84.02 | 2022-2023 | Accrufer |
| Allergan, INC. | $65.66 | 2019-2020 | |
| Exeltis, USA INC. | $56.71 | 2022-2025 | Slynd |
| Roche Diagnostics Corporation | $54.62 | 2019-2021 | |
| Becton, Dickinson and Company | $47.32 | 2022 | |
| Sumitomo Pharma America, INC. | $44.92 | 2025 | Myfembree, Gemtesa |
| Myriad Women'S Health, INC. | $44.17 | 2023 | Myrisk |
| Organon LLC | $37.97 | 2022-2023 | Nexplanon |
| Evofem Biosciences, INC. | $29.30 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $24.72 | 2022 | |
| Minerva Surgical, INC | $21.06 | 2023 | |
| Horizon Therapeutics Plc | $17.98 | 2019 | |
| Merck Sharp & Dohme LLC | $17.68 | 2019 | |
| Mycovia Pharmaceuticals, INC. | $16.12 | 2022 | |
| Coopersurgical, INC. | $15.25 | 2019 | |
| Ethicon US, LLC | $12.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Bailey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.